# Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease

> **NCT06168994** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 100 (estimated)

## Conditions studied

- Paroxysmal Atrial Fibrillation

## Interventions

- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT06168994
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-09-29
- **Final completion:** 2027-05-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168994, "Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06168994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*